VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Forum: Aktien Thema: Hauptdiskussion

Weiter: To date, Valneva has supplied approximately 80,000 doses of IXCHIQ(®) in the United States, Canada and Europe. No further SAEs have been reported since January 2025 globally, and Valneva has not identified any safety signal concerns that are inconsistent with the U.S. product label through its ongoing post- marketing safety monitoring, including its periodic safety reports and routine signal detection activities, which are shared with the U.S. Food and Drug Administration (FDA). Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, 'Valneva is committed to the highest standards of safety, and the safety profile of IXCHIQ(®) remains unchanged and positive. We respect the ACIP recommendation and agree on the importance of continuing the stringent safety surveillance protocols that are in place. We encourage providers to assess the benefit/risk of vaccination based on the individual's medical history and upcoming travel, in line with the current recommendation.' The recommendation from ACIP is pending final approval by the Director of the CDC and the U.S. Department of Health and Human Services. About Chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years(1). In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas(2). Between 2013 and 2023, more than 3.7 million cases were reported in the Americas(3) and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.(4)

Auf dütsch 18. April (Reuters) – Valneva SE: * VALNEVA AKTUALISIERT DIE ACIP-EMPFEHLUNG FÜR SEINEN CHIKUNGUNYA-IMPFSTOFF IXCHIQ® FÜR US-REISENDE * VALNEVA SE – CDC AKTUALISIERT DIE EMPFEHLUNG FÜR VALNEVAS CHIKUNGUNYA-IMPFSTOFF * VALNEVA SE – ACIP BEHÄLT DIE IXCHIQ-EMPFEHLUNG FÜR REISENDE IN AUSBRUCHSGEBIETE BEI ((Reuters.Briefs@thomsonreuters.com;))

April 18 (Reuters) - Valneva SE : * VALNEVA PROVIDES UPDATE ON ACIP RECOMMENDATION FOR ITS CHIKUNGUNYA VACCINE IXCHIQ® AMONG U.S. TRAVELERS * VALNEVA SE - CDC UPDATES RECOMMENDATION FOR VALNEVA'S CHIKUNGUNYA VACCINE * VALNEVA SE - ACIP MAINTAINS RECOMMENDATION FOR IXCHIQ FOR TRAVELERS TO OUTBREAK AREAS ((Reuters.Briefs@thomsonreuters.com;))

Saint Herblain (France), April 18, 2025 - Valneva SE (https://valneva.com/?lang=fr) (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ(®) for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHIQ(®) for persons aged >=18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered for persons aged >=18 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time e.g., six months or more. The ACIP also voted to recommend a precaution related to the use of IXCHIQ(®) in persons aged >=65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs), including five hospitalizations, among persons aged 67-86 years after vaccination with IXCHIQ(®). These SAEs were reported through the Vaccine Adverse Event Reporting System (VAERS), which is intended to be an early warning system to identify potential safety issues but generally cannot determine if adverse events are caused by a vaccine. All of the individuals who were hospitalized had pre-existing comorbidities, and ACIP concluded that while plausible, no causal association with IXCHIQ(®) could be determined for all cases and that further investigation is warranted. ACIP also noted that for individuals aged >=65 years, vaccination with IXCHIQ(® )might be indicated in certain higher-risk settings (e.g., outbreak), given the known risks for severe chikungunya disease and hospitalization in this age group. For example, earlier this month Valneva supplied 40,000 doses of IXCHIQ(®) to France's Island of La Réunion where the local public health agency, the Agence Régionale de Santé (ARS), is prioritizing vaccination of adults aged 65 and over, especially those with comorbidities, to protect residents during the ongoing chikungunya outbreak. Valneva recently received confirmation from ARS for an order of 50,000 additional doses of IXCHIQ(®) as part of its ongoing effort to manage this outbreak.

Richtig, Valneva ist eine wahre Perle! Von dieser Unternehmensführung können unsere Politiker in Deutschland noch was lernen! 🤣

Frohe Ostereiersuche 😀

🤓

Zielgruppe wird seit heute vergrößert. https://www.linfo.re/la-reunion/societe/depuis-ce-jeudi-la-vaccination-gratuite-contre-le-chikungunya-est-elargie-18-a-64-avec-des-comorbidites-et-65-ans-et-plus

Danke, das wünsche ich auch. Frohe Ostern 🐣🐇

95🚀

Ich wünsche Euch schöne dicke, bunte Eier! Frohe Ostern 👋

🤦

Hallo Nixblicker, Maxitaurus und Lapilli59

Hallo Nixblicker

Hallo Maxitaurus